Nutlin-3a

For research use only.

Catalog No.S8059 Synonyms: (-)-Nutlin-3

39 publications

Nutlin-3a Chemical Structure

Molecular Weight(MW): 581.49

Nutlin-3a, the active enantiomer of Nutlin-3, inhibits the p53/MDM2 interaction with IC50 of 90 nM in a cell-free assay. Nutlin-3a induces autophagy and apoptosis in a p53-dependent manner.

Size Price Stock Quantity  
USD 197 In stock
USD 670 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Selleck's Nutlin-3a has been cited by 39 publications

Purity & Quality Control

Choose Selective Mdm2 Inhibitors

Biological Activity

Description Nutlin-3a, the active enantiomer of Nutlin-3, inhibits the p53/MDM2 interaction with IC50 of 90 nM in a cell-free assay. Nutlin-3a induces autophagy and apoptosis in a p53-dependent manner.
Features Highly selective MDM2 inhibitor with a much lower effect on MDMX. Most effective on tumors with wild type p53.
Targets
p53/MDM2 interaction [3]
(Cell-free assay)
90 nM
In vitro

Nutlin-3a displaces p53 from the binding pocket of MDM2 and thereby releases p53 from inhibition and proteasomal degradation, leading to induction of its downstream targets, cell cycle arrest, and apoptosis. Seven days of incubation with 10 μM nutlin-3a led to >90% inhibition of NIH3T3 cells’ growth[1]. Nutlin-3a stabilizes and activates p53, and induces p21 expression in a dose-dependent manner[1]. Nutlin-3a effectively depletes the S-phase compartment to 0.2-2% and increases the G1- and G2/M-phase compartments[1]. Nutlin-3a induces apoptosis in ~60% of SJSA-1 and MHM cells after 40 h, which increased further after 60 h (85% and 65%, respectively) [1].

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
MV-4-11 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml\BTWM2OD1yLk[xNlM4KM7:TR?= M1fXUnNCVkeHUh?=
H4 MoXhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHj2cXJKSzVyPUCuOlYzQCEQvF2= NGnqZm9USU6JRWK=
PA-1 M4[yOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVjwTWtWUUN3ME2wMlg4ODl4IN88US=> NGjvbIpUSU6JRWK=
NKM-1 Moj4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWPJR|UxRTFwMES5N|Eh|ryP NH3SbmxUSU6JRWK=
NEC8 MkDrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnW1TWM2OD1zLkKxOVczKM7:TR?= NHuzc3pUSU6JRWK=
EoL-1-cell NFnyT5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXLJTG9uUUN3ME2xMlI3PzBzIN88US=> NX;QdZJbW0GQR1XS
K5 MojCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVfJR|UxRTFwNEKwO|Ih|ryP M2nQcXNCVkeHUh?=
QIMR-WIL MnHHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWPqPWxkUUN3ME2xMlYxQDV2IN88US=> NF;JWHVUSU6JRWK=
MOLT-16 NEnyZ5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4rrcmlEPTB;MT63PFYxPCEQvF2= NEPXUoFUSU6JRWK=
CHP-212 MkjlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1f6U2lEPTB;MT64NVM3QSEQvF2= NG\UWnFUSU6JRWK=
CTB-1 M4f3c2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlOwTWM2OD1{LkCyNlQ3KM7:TR?= NHnqOVVUSU6JRWK=
MOLT-4 NET2[WZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1PCc2lEPTB;Mj6zNlg2OyEQvF2= NX7aZm97W0GQR1XS
A101D M{i4b2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVzJR|UxRTJwM{WwNUDPxE1? NVK2XFJOW0GQR1XS
DOHH-2 NFrLO|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYX5eoFZUUN3ME2yMlQzOjd7IN88US=> NF7LfJJUSU6JRWK=
ES4 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NELVb|JKSzVyPUKuOFMyPTVizszN Moj2V2FPT0WU
SW780 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmjOTWM2OD1{LkWwPFg{KM7:TR?= NGLN[G1USU6JRWK=
VA-ES-BJ NInjOIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWjJR|UxRTJwNUSxNUDPxE1? MnP6V2FPT0WU
RPMI-8866 NVLpdGpTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHnWemRKSzVyPUKuOVYzOTRizszN NUHYZYU1W0GQR1XS
ML-2 M2rXS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXTJR|UxRTJwNU[1O|Yh|ryP M3fCOHNCVkeHUh?=
MSTO-211H MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWfJR|UxRTJwNUe0OVEh|ryP MVjTRW5ITVJ?
JVM-3 M{\uSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3jnc2lEPTB;Mj61PVMzPCEQvF2= Ml3sV2FPT0WU
A3-KAW MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn\1TWM2OD1{Lk[xPFE5KM7:TR?= MWnTRW5ITVJ?
DK-MG M3PQWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4TsOmlEPTB;Mj62NlQ4OSEQvF2= NWfo[FU3W0GQR1XS
LNCaP-Clone-FGC M1O2R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEjHSnBKSzVyPUKuOlQ{OThizszN MlHzV2FPT0WU
HT-144 MnrUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoTyTWM2OD1{Lk[0OVc4KM7:TR?= NYLaZoVjW0GQR1XS
NB69 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mm[wTWM2OD1{Lk[1N|M1KM7:TR?= MYjTRW5ITVJ?
A172 M2XXTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NETMephKSzVyPUKuOlc2QDhizszN M1\VSnNCVkeHUh?=
RS4-11 M1OwZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MojlTWM2OD1{LkeyOFA4KM7:TR?= M3TwPXNCVkeHUh?=
DU-4475 M13TVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHX0VXdKSzVyPUKuO|k2ODJizszN M1TlN3NCVkeHUh?=
SJSA-1 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkiwTWM2OD1{LkiyOVU3KM7:TR?= NWixS3lrW0GQR1XS
BV-173 NUfhXGhYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnTzTWM2OD1{Lki0OFM6KM7:TR?= NFP4ZlNUSU6JRWK=
U-2-OS NH\TSY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWnHcnQxUUN3ME2yMlkyODdizszN NVi1VGFlW0GQR1XS
CHP-134 M2PCb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYPJR|UxRTJwOUO4PFIh|ryP M4XEW3NCVkeHUh?=
D-502MG NFLvbI1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoXnTWM2OD1{Lkm3NVU1KM7:TR?= NULFTmI2W0GQR1XS
KS-1 NHjpWmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml3BTWM2OD1|LkCxOlI{KM7:TR?= MmDWV2FPT0WU
A204 NHfXfnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF7kN|VKSzVyPUOuNFU2QDhizszN NX7q[FZ{W0GQR1XS
KGN NWDIbmxUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmPyTWM2OD1|LkC4OFk3KM7:TR?= NXrFfVhWW0GQR1XS
NCI-H292 NYX4XIRTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV;jcYpNUUN3ME2zMlEzODJ6IN88US=> NIr1VYFUSU6JRWK=
CAKI-1 NWOzc2ZnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX;LWJdiUUN3ME2zMlEzPjl2IN88US=> M2D6[HNCVkeHUh?=
C2BBe1 MnnQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHXDenhKSzVyPUOuNVcxOjZizszN M1vSS3NCVkeHUh?=
NB10 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1fO[2lEPTB;Mz6yNFk3PiEQvF2= M4\1OnNCVkeHUh?=
MHH-NB-11 M1P0fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYLJR|UxRTNwMk[4Nlch|ryP MWDTRW5ITVJ?
NCI-SNU-1 NIfHdWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NILHUJRKSzVyPUOuNlc5PDNizszN MmLWV2FPT0WU
HCT-116 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkK0TWM2OD1|LkOwN|M2KM7:TR?= MnXpV2FPT0WU
G-401 MmrvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3fnbGlEPTB;Mz6zOlMzOiEQvF2= M4jqfHNCVkeHUh?=
MN-60 NH:5W5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVvieW5bUUN3ME2zMlQ1ODl{IN88US=> M2X5enNCVkeHUh?=
SW982 Mlu5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1XaUGlEPTB;Mz61NFg1QCEQvF2= NYLjUZd2W0GQR1XS
RKO M4TYOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWDVZYVsUUN3ME2zMlU{QTN4IN88US=> NF\PdYRUSU6JRWK=
D-283MED NYPjb5ZiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnHBTWM2OD1|LkW3PVg3KM7:TR?= MWrTRW5ITVJ?
LB996-RCC M2Dqc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYLjdpJFUUN3ME2zMlYzPTV6IN88US=> M{P0XHNCVkeHUh?=
A549 M2DHVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn\YTWM2OD1|Lk[zOVUzKM7:TR?= M2jyW3NCVkeHUh?=
LB2241-RCC MoX1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV3zNIRiUUN3ME2zMlY2PzB6IN88US=> NULQZmQyW0GQR1XS
SK-HEP-1 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4G5VWlEPTB;Mz63OFI6PyEQvF2= MYfTRW5ITVJ?
G-402 NHG5cJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGmwW5lKSzVyPUOuPFA5OzJizszN MlrxV2FPT0WU
GOTO MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFnzOohKSzVyPUOuPFQ{OzNizszN Ml\yV2FPT0WU
LOXIMVI MmDGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{fIcmlEPTB;Mz64OVY4PSEQvF2= NIDUVnhUSU6JRWK=
NH-12 M4ewXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4DhVGlEPTB;ND6wNVk2QSEQvF2= NIrDXVJUSU6JRWK=
CTV-1 M{TiOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mo\HTWM2OD12LkC3PVc{KM7:TR?= MkHMV2FPT0WU
CP50-MEL-B Mmf4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoXlTWM2OD12LkK0N|kzKM7:TR?= M4jNRnNCVkeHUh?=
RH-18 MmfwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWHRXIVHUUN3ME20MlI4PzB4IN88US=> NXjNTJRFW0GQR1XS
NB17 NYDRWlJuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4PaU2lEPTB;ND6zNVc3QCEQvF2= NHLjTnFUSU6JRWK=
A375 NV;KRmJwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX7JR|UxRTRwM{O1NlQh|ryP MWPTRW5ITVJ?
IST-MES1 NHXZ[YlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYLJR|UxRTRwNEG0NVEh|ryP MVXTRW5ITVJ?
MZ2-MEL NVTpN21CT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYfJR|UxRTRwNUCxOVUh|ryP M2j1VHNCVkeHUh?=
CAL-54 NHH1[3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1jZRWlEPTB;ND61N|AyQSEQvF2= M4\CTXNCVkeHUh?=
NCI-H28 M{HNXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWrJR|UxRTRwNkK3NVch|ryP M3PoNXNCVkeHUh?=
D-247MG NWi1XHFlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUnJR|UxRTRwN{WwO|Ih|ryP MUHTRW5ITVJ?
NCI-H460 NYXTZ4IxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUjJR|UxRTRwOUGxNlch|ryP MWXTRW5ITVJ?
MCF7 NE\ZcYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkjNTWM2OD13LkS0NlQ1KM7:TR?= MUnTRW5ITVJ?
697 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{i0eWlEPTB;NT60OFU2KM7:TR?= M1fnXHNCVkeHUh?=
ONS-76 NWrERXpFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUDUVIFoUUN3ME21MlU4ODB7IN88US=> M4fJRXNCVkeHUh?=
C32 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV;qcoRQUUN3ME21MlYxODJ7IN88US=> NVLORXFkW0GQR1XS
OS-RC-2 MojiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1HTOWlEPTB;NT63N|g5PyEQvF2= M1y2d3NCVkeHUh?=
MEL-HO Ml\vS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGjyZW5KSzVyPUWuPFU3PjdizszN NEjGRnJUSU6JRWK=
LoVo NY\Ubo5rT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVPJR|UxRTZwMEG2NlQh|ryP MnjLV2FPT0WU
AGS M2TrdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn\0TWM2OD14LkG0PFI5KM7:TR?= MYXTRW5ITVJ?
GI-ME-N NFjlZ|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MonGTWM2OD14LkKyOFIyKM7:TR?= MUTTRW5ITVJ?
H-EMC-SS MlLTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGLofldKSzVyPU[uN|g3KM7:TR?= NF[xfFFUSU6JRWK=
RVH-421 NF3FPFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIi2eFhKSzVyPU[uOFI1OjhizszN NEKz[4xUSU6JRWK=
SW954 MnfNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlPITWM2OD14LkW1OVczKM7:TR?= NWP5VHozW0GQR1XS
NB5 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXfJR|UxRTZwNU[xPFMh|ryP Mnr3V2FPT0WU
NCI-H2122 MkiyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWnJR|UxRTZwNUi3PVMh|ryP NGHoO25USU6JRWK=
AM-38 NH\xU5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUHJR|UxRTZwN{W2N|kh|ryP NIrlb2hUSU6JRWK=
KNS-81-FD NUXrXlJZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUnJR|UxRTZwN{[0PVQh|ryP NGDZSIJUSU6JRWK=
LS-513 MkD5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M33vfGlEPTB;Nj63PVAzPiEQvF2= M3rhZXNCVkeHUh?=
A427 MofsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{TCd2lEPTB;Nj64O|gzQSEQvF2= NILBeZVUSU6JRWK=
WM-115 NUXjO5RJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWrJR|UxRTZwOUOyN{DPxE1? MX7TRW5ITVJ?
COLO-829 M2nvWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVzJR|UxRTdwMkSxPFgh|ryP NWfxRVBZW0GQR1XS
NCI-H1650 MkD3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVrXbpJPUUN3ME23MlM6OjJ6IN88US=> NEmxN4VUSU6JRWK=
NCI-H358 MkfWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{nmTmlEPTB;Nz60OFg4QSEQvF2= M2\wSHNCVkeHUh?=
HT-1080 NUT2WFhiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXjJR|UxRTdwNEiyOVQh|ryP MXXTRW5ITVJ?
HCC2218 NV[xSZpwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWnJR|UxRTdwNkK5O{DPxE1? NFHXeItUSU6JRWK=
NCI-H661 NHnIdVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoLKTWM2OD15Lki3NFY6KM7:TR?= M1\EdHNCVkeHUh?=
KM-H2 NGi4enhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVTFdZlQUUN3ME23Mlg5Pjl2IN88US=> MXPTRW5ITVJ?
RPMI-2650 NFnNbFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX62OnBEUUN3ME23Mlk1PDF2IN88US=> NEfNepBUSU6JRWK=
NCI-H226 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWLJR|UxRThwMkGxNlIh|ryP M1\Lc3NCVkeHUh?=
MKN45 NYDpNWZsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXzJR|UxRThwMk[2NFIh|ryP NUDzbIE4W0GQR1XS
D-392MG NF;G[YhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYrJR|UxRThwNUK3NlIh|ryP NGnQPZdUSU6JRWK=
RCC10RGB NYHxd45ST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4jJR2lEPTB;OD64OlY6PSEQvF2= MXjTRW5ITVJ?
CAL-51 M4PrOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NG\5b4JKSzVyPUmuNVAzPTFizszN Mn7SV2FPT0WU
COLO-678 M171bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWTJR|UxRTlwM{K4NVEh|ryP NXHnR4ZjW0GQR1XS
SK-MEL-24 NEPBcZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{TReGlEPTB;OT61OVg2PiEQvF2= M3KxfHNCVkeHUh?=
SK-MEL-30 NECz[YZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYDJR|UxRTlwOUS0O|Yh|ryP MlnlV2FPT0WU
MMAC-SF NFH3VnFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUG3UHVLUUN3ME2xNE4{QTZzIN88US=> NF7GPI5USU6JRWK=
NTERA-S-cl-D1 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml[wTWM2OD1zMD62OVA5KM7:TR?= NWLTRm56W0GQR1XS
NB12 Mm\4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYLJR|UxRTFzLkWwN{DPxE1? MlLzV2FPT0WU
UACC-257 NWrXdmNtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVjJR|UxRTFzLki2PVUh|ryP MYrTRW5ITVJ?
LAN-6 NUjRSmQxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYDpeGtGUUN3ME2xNU46QTJ6IN88US=> MoLVV2FPT0WU
SW1573 M4XJcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlfRTWM2OD1zMj6zNFg3KM7:TR?= NVLHcXJUW0GQR1XS
NMC-G1 MoS3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVjJR|UxRTF{LkSxO|Uh|ryP Mm\mV2FPT0WU
SHP-77 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmD2TWM2OD1zMj61OVc1KM7:TR?= NFjIT|FUSU6JRWK=
IGROV-1 NXnYNXJQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NULUTG9{UUN3ME2xNk43PTd|IN88US=> Ml2yV2FPT0WU
22RV1 NWnnfINiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXzJR|UxRTF{LkiwOVkh|ryP M4jDNXNCVkeHUh?=
SK-MEL-3 NWfaW3VMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUXFfVZUUUN3ME2xN{4{QTd|IN88US=> M1[3XXNCVkeHUh?=
NCI-H1563 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV7lZ3ZLUUN3ME2xN{41OjB{IN88US=> NIPKW5ZUSU6JRWK=
IGR-1 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVnJR|UxRTF2LkCzOFch|ryP NWrqdXNYW0GQR1XS
EW-3 MoXNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX3JR|UxRTF2LkG2N|kh|ryP MVrTRW5ITVJ?
JEG-3 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHHYbFZKSzVyPUG0MlQ6PTNizszN NWjxfmRjW0GQR1XS
ES3 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlzCTWM2OD1zND62OVYzKM7:TR?= MXzTRW5ITVJ?
MDA-MB-175-VII MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFvwZ3ZKSzVyPUG0MlcyOTFizszN MmXnV2FPT0WU
P30-OHK M1njUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUHJR|UxRTF3LkC0PVYh|ryP MYLTRW5ITVJ?
GP5d M2S5T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXT2T4NFUUN3ME2xOU4yPDZ4IN88US=> MV\TRW5ITVJ?
HMV-II MlL4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M160O2lEPTB;MUWuN|M{OyEQvF2= MWjTRW5ITVJ?
COLO-679 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYrJR|UxRTF3LkWwNUDPxE1? M1W1ZXNCVkeHUh?=
JAR M17WUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWPJR|UxRTF3LkeyNFUh|ryP MUDTRW5ITVJ?
NCI-H1666 NWjPPGNCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYHJR|UxRTF3LkmzPVkh|ryP NH74c4tUSU6JRWK=
SW48 MofZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{LlRmlEPTB;MUWuPVUyPiEQvF2= M13wVHNCVkeHUh?=
NCI-H720 NFz3SGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoLETWM2OD1zNT65PVg6KM7:TR?= NVPzbJhGW0GQR1XS
HT-1197 NVfjdI9LT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3HZUGlEPTB;MU[uNFM2OiEQvF2= MU\TRW5ITVJ?
HL-60 M4XaV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M13QW2lEPTB;MU[uNFM5PCEQvF2= NHfW[YpUSU6JRWK=
BEN NUPESZg6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXvJR|UxRTF4LkW2N|gh|ryP MlfVV2FPT0WU
HAL-01 NFf3b2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{S2d2lEPTB;MU[uPFkxQSEQvF2= M3\6ZXNCVkeHUh?=
SW900 NUPVe4h2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWPJR|UxRTF4LkmxN|Ih|ryP NIW1ZpVUSU6JRWK=
SBC-1 MlzJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoTDTWM2OD1zNz61OFI6KM7:TR?= MlXmV2FPT0WU
SH-4 NUnoXVVLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoHqTWM2OD1zNz61PFQyKM7:TR?= NFTS[ppUSU6JRWK=
UACC-62 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXvJR|UxRTF5Lke2N|ch|ryP M4LzbHNCVkeHUh?=
BHT-101 MkLkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFmxTmFKSzVyPUG5Mlg4ODVizszN NHrSTmJUSU6JRWK=
DB MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml[wTWM2OD1{MT61OlQ6KM7:TR?= M1XKVXNCVkeHUh?=
SK-MEL-1 M4[yUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkjXTWM2OD1{MT61PFczKM7:TR?= M{jnXnNCVkeHUh?=
NCI-H747 M17nTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M13nZWlEPTB;MkKuO|M4QSEQvF2= MnuyV2FPT0WU
SK-LU-1 M4L3T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn3CTWM2OD1{Mz6zOVI1KM7:TR?= Mkn1V2FPT0WU
KG-1 NUm2O2FFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mm\nTWM2OD1{Mz60PVQ3KM7:TR?= M{DUVHNCVkeHUh?=
LXF-289 M{HzPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlHjTWM2OD1{Mz63NVQh|ryP M{fi[XNCVkeHUh?=
HCC1954 NV7ZfYRpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoPkTWM2OD1{ND64PFQ1KM7:TR?= MY\TRW5ITVJ?
Ramos-2G6-4C10 NYn3fIVDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MojZTWM2OD1{Nj60PVgyKM7:TR?= NX35fVVGW0GQR1XS
DBTRG-05MG M33k[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnnTTWM2OD1{Nj62OFg5KM7:TR?= MVfTRW5ITVJ?
NCI-H2052 NV;PN406T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYrPV2xIUUN3ME2yO{42Pjh2IN88US=> M4K4U3NCVkeHUh?=
RMG-I Mo[1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUTJR|UxRTJ7LkSxN|kh|ryP NXq2[VlvW0GQR1XS
H9 NGHaTVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXXD[GlnUUN3ME2zNU4{ODB6IN88US=> MWfTRW5ITVJ?
GR-ST Ml2zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MU\JR|UxRTN{LkS0OVMh|ryP MULTRW5ITVJ?
Mo-T MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmjnTWM2OD1|Mj61NFQ3KM7:TR?= NXvRcXlbW0GQR1XS
SW1088 NHfBb|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEnQPGZKSzVyPUOyMlk5ODFizszN NFzXTY9USU6JRWK=
LB2518-MEL MnfoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnfoTWM2OD1|Mz6wO|k4KM7:TR?= NHXJOWNUSU6JRWK=
NCI-H82 M2TLeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWXJR|UxRTN|LkG2OlEh|ryP MVrTRW5ITVJ?
LAMA-84 NHqyWXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2XCdmlEPTB;M{SuOlA4OyEQvF2= M3\Fd3NCVkeHUh?=
KYSE-450 MonVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYDJR|UxRTN2Lk[3O|Yh|ryP NULLdXFJW0GQR1XS
LU-99A MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NELSTHZKSzVyPUO1MlAxODdizszN MYjTRW5ITVJ?
BE-13 MlLIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4TucGlEPTB;M{WuOlU1PSEQvF2= NVmxbYFnW0GQR1XS
GAK MoXQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYDJR|UxRTN3Lk[5OUDPxE1? NFzqVJRUSU6JRWK=
NCI-H1573 M{XoNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3vsUGlEPTB;M{WuPFgyQCEQvF2= M2fCUXNCVkeHUh?=
AsPC-1 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3\6NGlEPTB;M{[uNVUzPyEQvF2= Ml6yV2FPT0WU
HDLM-2 NX3P[Gh1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYrJR|UxRTN4LkOxOkDPxE1? Ml3UV2FPT0WU
NCI-H441 M{f4[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWHJR|UxRTN5LkC2PVEh|ryP M{DHZ3NCVkeHUh?=
CAL-27 NVT6PJY4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn\kTWM2OD1|Nz63NlMyKM7:TR?= NEjvc|dUSU6JRWK=
OVCAR-3 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF7nbXBKSzVyPUO5MlMyQDFizszN M1j3[3NCVkeHUh?=
RPMI-8226 NI\IWWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4rFVWlEPTB;M{muOVk5KM7:TR?= Ml3uV2FPT0WU
EFO-21 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWXZclFoUUN3ME20NE42QDF2IN88US=> NYi5RXI3W0GQR1XS
SNU-C2B MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFX3VHlKSzVyPUSxMlUxQDRizszN M2jhRXNCVkeHUh?=
VM-CUB-1 NX;QRW9ZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUTJR|UxRTR|LkiwN|ch|ryP M1TLOXNCVkeHUh?=
NCI-H2087 NInUSllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NW\MT5ZwUUN3ME20OU4xOjN|IN88US=> NFvVeJlUSU6JRWK=
EW-16 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUHDZ29EUUN3ME20Ok4{OTN5IN88US=> MkKxV2FPT0WU
SK-N-AS NV;HZWN[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3vhZ2lEPTB;NE[uO|E3PyEQvF2= NH3GbWJUSU6JRWK=
COR-L105 M3;0PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3vkcWlEPTB;NE[uPFg2PyEQvF2= MYXTRW5ITVJ?
DEL MnzrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NETSVZdKSzVyPUS4MlA1OjlizszN NUTXT2J2W0GQR1XS
JVM-2 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHHtW4ZKSzVyPUS4MlA2PThizszN MkXNV2FPT0WU
KARPAS-45 NEjBTnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYryS3NQUUN3ME20PU41PTN6IN88US=> NYXsO4R3W0GQR1XS

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
p53 / MDM2 / p21 / Bax / Bak / Noxa / cleaved caspase / pro-caspase; 

PubMed: 16014563     


Expression of apoptosis- and cell-cycle–associated proteins in OCI-AML-3 cells, which were treated with 5 μM Nutlin-3a for the indicated times. Nutlin-3a induced increased protein expression of p53, MDM2, and p21 in OCI-AML-3 cells in a time-dependent fashion. Nutlin-3a induced Noxa, a BH3-only member of the Bcl-2 family, followed by caspase activation. β-actin was used to confirm equal loading of proteins. Arrowheads indicate cleared caspases.

BMI-1; 

PubMed: 26887044     


Western blot analysis of BMI-1 and actin was performed in BV-173, SUP-B15, NALM-6, NALM-19 and REH cell lines after 24 hours treatment with increasing concentrations of Nutlin-3a (1 μM, 2 μM, 5 μM) and with DMSO control. 

p53-Ser15 / p53-Ser37 / p53-Lys382 / MDM2 / CDC2 / PLK1 / HSC70; 

PubMed: 23666059     


Expression of the indicated proteins in whole-cell lysates of cells treated for 96 h with 50 μM resveratrol (R), 5 μM nutlin-3a (N), or co-treated with both substances (RN).

16014563 26887044 23666059
Immunofluorescence
p-p21 / β-actin; 

PubMed: 31083332     


Cells were treated with fluoride (5 mM) with/without Nutlin-3a for 24 h. p-p21 (green), nucleus (DAPI; blue) and β-actin (red) expression were detected by immunocytochemistry. Nutlin-3a addition augmented p-p21 expression compared to NaF treatment alone.

P53; 

PubMed: 21394100     


At 12 h following treatment with nutlin-3a, DoHH2 and MCA cells had increased levels of p53 visualized by immunofluorescence. p53 localization was predominantly nuclear. The 4',6-diamidino-2-phenylindole was used as counterstain of the nuclei.

Ac-p300; 

PubMed: 30240745     


HepG2 cells were treated with 5 μM Nutlin-3a for 24 hr, and the levels of Ac-p300 and p53 were assessed by co-immunofluorescence. Fluorescence intensity of Ac-p300 in control cells versus Nutlin-3a-treated cells have been quantified (represented as mean ± SD, unpaired two-tailed Student's t test, n = 50 of three independent experiments). Scale bar, 10 μm.

31083332 21394100 30240745
Growth inhibition assay
Cell viability; 

PubMed: 26248031     


All 15 cell lines were plated in 96-well plates. After 24h, media was exchanged and cells were treated with incremental concentrations of Nutlin-3a (1 μM, 5 μM, 10 μM, 25 μM, 50 μM, and 70 μM). After 72h of Nutlin-3a treatment, cell viability was measured by WST assay and compared to untreated control.

26248031
In vivo Nutlin-3a suppresses xenograft growth in a dose-dependent fashion with the highest dose (200 mg/kg) showing a substantial tumor shrinkage [1]. Nutlin-3 is a selective activator of the p53 pathway in vivo and highly efficacious against SJSA-1 osteosarcoma tumors[1]. Tumors with wild-type p53 and mdm2 gene amplification will respond best to therapy with Nutlin-3a.

Protocol

Kinase Assay:[3]
- Collapse

Biacore studies:

Competition assays are performed on a Biacore S51. A Series S Sensor chip CM5 is derivatized for immobilization of a PentaHis antibody for capture of the His-tagged p53. The level of capture is ~ 200 response units (1 response unit corresponds to 1 pg of protein per mm 2). The concentration of MDM2 protein is kept constant at 300 nM. Test compounds are dissolved in DMSO at 10 mM and further diluted to make a concentration series of inhibitor in each MDM2 test sample. The assays are run at 25 °C in running buffer (10 mM Hepes, 0.15 M NaCl, 2% DMSO). MDM2-p53 binding in the presence of inhibitor is calculated as a percentage of binding in the absence of inhibitor and IC50 is calculated using Microsoft Excel
Cell Research:[2]
- Collapse
  • Cell lines: OSA, T778, RMS13, U2OS, SaOS-2
  • Concentrations: ~5 μM
  • Incubation Time: 120 h
  • Method: SRB
    (Only for Reference)
Animal Research:[1]
- Collapse
  • Animal Models: SJSA-1 xenograft
  • Dosages: 50, 100, 200 mg/kg twice daily
  • Administration: oral
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 100 mg/mL (171.97 mM)
Water Insoluble
Ethanol '100 mg/mL
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
5% DMSO+55% PEG 300+ddH2O
For best results, use promptly after mixing.
8mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 581.49
Formula

C30H30Cl2N4O4

CAS No. 675576-98-4
Storage powder
in solvent
Synonyms (-)-Nutlin-3
Smiles CC(C)OC1=C(C=CC(=C1)OC)C2=NC(C(N2C(=O)N3CCNC(=O)C3)C4=CC=C(C=C4)Cl)C5=CC=C(C=C5)Cl

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Dosage mg/kg Average weight of animals g Dosing volume per animal ul Number of animals
Step 2: Enter the in vivo formulation ()
% DMSO % % Tween 80 % ddH2O
CalculateReset

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    What is the difference between S1061 (Nutlin-3) and S8059 (Nutlin-3a)?

  • Answer:

    S1061 is a racemic mixture of Nutlin3a and Nutlin3b. s8059 is the active enantiomer of Nutlin3.

Mdm2 Signaling Pathway Map

Related Mdm2 Products

Tags: buy Nutlin-3a | Nutlin-3a supplier | purchase Nutlin-3a | Nutlin-3a cost | Nutlin-3a manufacturer | order Nutlin-3a | Nutlin-3a distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID